Spatially Resolved Transcriptomics Companies & Product in Doha

Featured Genomic & Transcriptomic Solutions

[Copy] Eukaryotic mRNA Sequencing-NGS

Human Whole Genome Sequencing

Small RNA Sequencing-Illumina

GWAS

Doha's Biotech Landscape: Embracing Spatially Resolved Transcriptomics

Doha, the vibrant capital of Qatar, is rapidly transforming into a world-class hub for biomedical research, precision medicine, and biotechnology innovations. Backed by the visionary goals of Qatar National Vision 2030, the city has channeled significant resources into developing state-of-the-art healthcare infrastructure and high-impact scientific research programs. At the center of this biological renaissance is the adoption of Spatially Resolved Transcriptomics (SRT), a revolutionary methodology that enables scientists to map gene expression patterns within intact tissue sections. Unlike traditional bulk sequencing or single-cell RNA sequencing, which lose spatial coordinates during sample preparation, SRT preserves the spatial context, unlocking new frontiers in tissue architecture and cellular communication.

Local scientific leaders in Doha, including institutions like Sidra Medicine, Hamad Bin Khalifa University (HBKU), Qatar Biobank, and the National Center for Cancer Care and Research (NCCCR), are actively integrating spatial genomics into their research pipelines. This localization of spatial biology is critical for addressing specific regional health concerns, such as oncology, rare genetic diseases, and metabolic disorders, which display unique genetic profiles within the Middle Eastern population. By partnering with global pioneers like Biomarker Technologies (BMKGene), research laboratories in Doha can leverage cutting-edge platforms to decode complex cellular microenvironments at subcellular resolution.

Why Spatial Resolution Matters in Doha's Precision Medicine

Traditional transcriptomics methods provide a "smoothie" of genetic information, masking cell-to-cell variations and their structural relationships. Spatially Resolved Transcriptomics acts as a high-definition map, allowing researchers to see exactly where specific genes are activated. This is vital for developing targeted therapies and understanding tissue pathology in real time.

Global Industry Trends & Localized Application Scenarios

The global spatial biology market is undergoing exponential growth, driven by advancements in high-throughput sequencing technologies, automated tissue processing, and AI-driven bioinformatics pipelines. Key industry trends indicate a strong shift towards multi-omics integration, where spatial transcriptomics is combined with spatial proteomics and epigenomics to construct a comprehensive atlas of tissue biology. Furthermore, the development of subcellular resolution technologies, such as BMKGene’s proprietary BMKMANU S3000 spatial transcriptome technology, is setting new benchmarks for research precision.

Oncology & Immunology

Mapping the tumor microenvironment (TME) to understand cancer heterogeneity, immune escape mechanisms, and predict patient responses to immunotherapy at NCCCR Doha.

Rare Genetic Diseases

Investigating developmental disorders and tissue pathology linked to consanguinity in the region, supporting Sidra Medicine’s pediatric genomic initiatives.

Agricultural Genomics

Analyzing stress-adaptation mechanisms in desert plants and marine organisms native to the Arabian Gulf, assisting local food security programs.

In Doha, localized application scenarios are particularly focused on translating academic discoveries into clinical workflows. By using spatial transcriptomics, local pathologists can delineate tissue margins with extreme precision, classifying tumors based on spatial cellular architecture rather than morphology alone. Additionally, in the agricultural sector, researchers use spatial transcriptomic tools to study plant-pathogen interactions in date palms, helping to engineer drought-resistant and salinity-tolerant agricultural products suitable for Qatar's arid climate.

About Biomarker Technologies (BMKGene)

Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics.

Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.

Our presence in Doha and the wider Middle East region empowers scientific groups to execute complex spatial sequencing projects efficiently, ensuring top-tier data generation, strict quality control, and deep bioinformatic insights customized for local scientific demands.

Professional, Automatic Molecular Laboratory

Our Scientific & Computational Platforms

Sequencing Platforms

PacBio platforms: Sequel II, Sequel, RSII

Nanopore platforms: PromethION P48, GridION X5 MinION

10X Genomics: 10X ChromiumX, 10X Chromium Controller

Illumina platforms: NovaSeq

BGI-sequencing platforms: DNBSEQ-G400, DNBSEQ-T7

Bionano Irys system

Waters XEVO G2-XS QTOF

QTRAP 6500+

World-Class Labs

Over 20,000 square feet place

Advanced biomolecular laboratory instruments.

Standard labs of sample extraction, library construction, clean rooms, sequencing labs.

Standard procedures from sample extraction to sequencing under strict SOPs.

BMKCloud Platform

Reliable, Easy-to-use Online Analysis

Self-developed BMKCloud bioinformatics platform.

CPUs with 41,104 memory and 3 PB total storage.

4,260 computing cores with peak computing power over 121,708.8 Gflop per second.

Leading, Multi-level High-throughput Sequencing Platforms

Multiple and flexible experimental designs fulfilling diverse research goals

Brilliant Lab 1000: Fully Automated NGS Platform

Fully Automated Platform for Next-generation sequencing--Brilliant Lab 1000

Biomarker technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to the high-throughput NGS library construction service.

BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.

This automated system ensures that high-throughput clinical and research projects in Doha receive highly reproducible, contamination-free results with industry-leading turnaround times.

Enterprise Qualifications & Scientific Patents

Our commitment to quality and research integrity is backed by globally recognized certifications, quality management standards, and a robust intellectual property portfolio.